Annual Shareholders Meeting Set for May 12, 2006
BOCA RATON, Fla., Jan. 11 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) will announce 2005 fourth quarter and year-
end financial results on Thursday, February 23, 2006, after market close. The
company will also host a live webcast at 4:30 p.m. ET.
The live webcast can be accessed at http://audioevent.mshow.com/284694 or
via the Nabi Biopharmaceuticals website at http://www.nabi.com . If you do
not have Internet access, the U.S./Canada call-in number is 877-569-0953
conference code 4182747, and the international call-in number is 706-634-4967
conference code 4182747. An audio replay will be available for U.S./Canada
callers at 800-642-1687 conference code 4182747, and for international callers
at 706-645-9291 conference code 4182747.
An archived version of the webcast will be available at the same Internet
address through March 2, 2006. The audio replay will also be available
through March 2, 2006. The press release will be available on the company's
website at http://www.nabi.com .
Nabi Biopharmaceuticals also announced today that its Annual Meeting of
Shareholders will be held on Friday, May 12, 2006, in Boca Raton, Florida, at
10:00 a.m. ET at the Renaissance Boca Raton Hotel, Coral Ballrooms B, C and D,
2000 NW 19th Street (Phone: 561-388-5252).
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering
the immune system to develop and market products that fight serious medical
conditions. We are focusing on developing products addressing commercial
opportunities in our core business areas: Gram-positive bacterial infections,
hepatitis, kidney disease (nephrology), and nicotine addiction. We have three
products on the market today: PhosLo(R) (calcium acetate), Nabi-HB(R)
[Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol sodium
(for injection)] and a number of products in various stages of clinical and
pre-clinical development. The company also filed Marketing Authorization
Applications (MAA) in Europe to market Nabi-HB(R) Intravenous [Hepatitis B
Immune Globulin (Human) Intravenous] under the trade name HEBIG(TM) for the
prevention of hepatitis B disease in HBV-positive liver transplant patients;
and for PhosLo, which is already marketed in the United States. The company's
products in development include NicVAX, a vaccine to treat nicotine addiction,
and Civacir, an antibody for preventing hepatitis C virus re-infection in
liver transplant patients. For additional information on Nabi
Biopharmaceuticals, please visit our Website: http://www.nabi.com .
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
Audio:http://audioevent.mshow.com/284694
CONTACT:
Constance C. Bienfait, Vice President,
Investor Relations, Nabi Biopharmaceuticals, +1-561-989-5800
|
